SEC 13F Intelligence

Managers / Q4 2025 · view latest →

Kalehua Capital Management LLC

CIK 0002106181 · 3819 MAPLE AVENUE, DALLAS, TX, 75219 · 214-225-0846

Reported Value
$101M
Q4 2025
Positions
19
Filings on Record
3
2019–present window
Filed
Feb 13, 2026
original filing

Summary

Kalehua Capital Management LLC reported $101M in U.S.-listed holdings across 19 positions for Q4 2025.

The portfolio is heavily concentrated: Alpha Architect 1 3 Month Box Etf alone accounts for 26.3% of reported value.

Portfolio Metrics

Top-10 Concentration
+83.5%
share of reported value
Largest Position
+26.3%
Alpha Architect 1 3 Month Box Etf

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’25: $101MQ4 ’25Q1 ’26: $260MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 62.7%ETP: 26.3%ADR: 5.6%Other: 5.5%
  • Common Stock · 62.7% · $63M
  • ETP · 26.3% · $27M
  • ADR · 5.6% · $6M
  • Other · 5.5% · $6M

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
Alpha Architect 1-3 Month Box EtfNEW+230.8K230.8K+$27M$27M
XFORX4 Pharmaceuticals IncNEW+3.72M3.72M+$15M$15M
SIONSionna Therapeutics IncNEW+197.1K197.1K+$8M$8M
RLAYRelay Therapeutics IncNEW+901.5K901.5K+$8M$8M
CMPSCompass Pathways PlcNEW+819.7K819.7K+$6M$6M
Pharvaris NVNEW+198.8K198.8K+$6M$6M
SEPNSepterna IncNEW+194.5K194.5K+$5M$5M
ORKAOruka Therapeutics IncNEW+118.5K118.5K+$4M$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2025

19 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1Alpha Architect 1-3 Month Box EtfALPHA ARCH 1-326.27%$27M230.8K
2XFORX4 Pharmaceuticals Inchistory →COM NEW14.73%$15M3.72M
3SIONSionna Therapeutics Inchistory →COM8.02%$8M197.1K
4RLAYRelay Therapeutics Inchistory →COM7.54%$8M901.5K
5CMPSCompass Pathways Plchistory →SPONSORED ADS5.59%$6M819.7K
6Pharvaris NVCOM5.46%$6M198.8K
7SEPNSepterna Inchistory →COM5.36%$5M194.5K
8ORKAOruka Therapeutics Inchistory →COM3.55%$4M118.5K
9IKTInhibikase Therapeutics Inchistory →COM NEW3.55%$4M1.75M
10ALLOAllogene Therapeutics Inchistory →COM3.45%$3M2.55M
11LONALeonaBio Inchistory →COM2.95%$3M393.7K
12MLTXMoonLake Immunotherapeuticshistory →CLASS A ORD2.29%$2M175.7K
13ORICOric Pharmaceuticals Inchistory →COM2.16%$2M267.1K
14VRCAVerrica Pharmaceuticals Inchistory →COM SHS1.94%$2M235.8K
15TYRATyra Biosciences Inchistory →COM1.94%$2M74.5K
16SRZNSurrozen Inchistory →COM NEW1.87%$2M385.2K
17TNYATenaya Therapeutics Inchistory →COM1.41%$1M2.00M
18KLRSKalaris Therapeutics Inchistory →COM1.17%$1M139.9K
19DMACDiamedica Therapeutics IncCOM NEW0.75%$759,05895.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026REVEALED$260M50May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$101M19Feb 13, 202613F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.